Pelthos Therapeutics (PTHS) Investor presentation summary

Strategic focus and product portfolio

• Commercial biopharma company specializing in differentiated treatments for cutaneous infections, leveraging recent acquisitions to expand its portfolio and market reach.

• Portfolio includes Zelsuvmi (berdazimer) for molluscum contagiosum, Xepi (ozenoxacin) for impetigo, and Xeglyze (abametapir) for head lice, each targeting large, underserved markets.

• Zelsuvmi launched in July 2025 as the first and only at-home prescription treatment for molluscum contagiosum.

• Xepi and Xeglyze, both FDA-approved, are expected to launch in late 2026 and the first half of 2027, respectively, leveraging existing commercial infrastructure.

• All products utilize a unified sales team, maximizing operating leverage and minimizing overhead.

Market opportunity and commercial execution

• Zelsuvmi addresses a U.S. market with 17 million infected and 3–6 million children affected annually; peak net revenue forecast of $175M by 2028.

• Zelsuvmi achieved strong launch metrics: 8,948 units prescribed and 2,712 unique prescribers in Q3–Q4 2025.

• Coverage expanded to 70% of combined Medicaid/commercial lives by Q1 2026, with favorable approval rates and gross-to-net margins.

• Sales team expanded to 64 territories, targeting key prescribers in major U.S. markets.

• Robust marketing includes national conferences, digital campaigns, and patient support programs.

Clinical efficacy and differentiation

• Zelsuvmi demonstrated statistically significant efficacy in Phase 3 trials, with 32.4% of patients achieving complete clearance at 12 weeks versus 19.7% for control.

• Mean and median lesion count reductions were 58% and 82% for Zelsuvmi, outperforming vehicle control.

• Xepi and Xeglyze both offer first-line treatments with strong clinical data and address growing resistance to existing therapies.

• All products have exclusivity extending into the next decade, supported by strong patent protection and complex manufacturing.